Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Forte Biosciences, Inc.NASDAQ: FBRX
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $1.48M, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 2.2% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.04M USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.04M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Other non-current liabilities amounts to 2.2% of total assets for FBRX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 8.25M CHF | +173.2% | +48.2% | 9.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $3.6M USD | +21.5% | +205.2% | 15.9% |
| Mar 2026 | $2.48M USD | -53.5% | -14.7% | 0.9% | |
| Mar 2026 | $1.77M USD | +27.0% | +31.8% | 0.7% | |
| Mar 2026 | $1.48M USD | — | — | 2.2% | |
| Mar 2026 | $87K USD | +0.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | -100.0% | — | 0.0% |
| Peer median (excluding FBRX) | — | +10.8% | +40.0% | 0.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.